Dachaigh › Ailseachadh nan Sgamhan › North Carolina › Durham
Sgrùdaidhean clionaigeach Ailseachadh nan Sgamhan ann an Durham, NC
Tha 32 sgrùdaidhean airson Ailseachadh nan Sgamhan a’ lorg phàirtichean aig làraichean ann agus timcheall air Durham (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
A’ fastadhÌre 3
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- Duke University, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Durham VA Medical Center, Durham
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
A’ fastadhÌre 3
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
A’ fastadhÌre 3
- Duke Cancer Center, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A’ fastadhÌre 3
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mìle air falbh
A Study of PHN-012 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1
- PHN-012-001 Site, Durham
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
A’ fastadhÌre 3
- Duke University Medical Center, Durham
Study of Trilaciclib and Lurbinectidin
A’ fastadhÌre 2
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill · 10 mìle air falbh
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
A’ fastadhÌre 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10 mìle air falbh
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
A’ fastadhÌre 1/2
- Duke University School of Medicine, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
A’ fastadhÌre 2
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 10 mìle air falbh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A’ fastadhÌre 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10 mìle air falbh
The Vanguard Study: Testing a New Way to Screen for Cancer
A’ fastadhFàilte do shaor-thoilich fhallain
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
Health Education Approach to Lung Screening
A’ fastadhFàilte do shaor-thoilich fhallain
- University of North Carolina-Chapel Hill, Carrboro · 11 mìle air falbh
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
A’ fastadhÌre 1
- Xencor Investigative Site, Durham
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
A’ fastadhÌre 1/2
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
A’ fastadh
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mìle air falbh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
A’ fastadhÌre 2
- University of North Carolina, Chapel Hill · 10 mìle air falbh
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
A’ fastadhÌre 1
- Research Site, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
A’ fastadhÌre 1
- Duke Cancer Center, Durham
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
A’ fastadhÌre 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2/3
- Durham VA Medical Center, Durham
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
A’ fastadhFàilte do shaor-thoilich fhallain
- Duke University, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
A’ fastadh
- Durham VA Medical Center, Durham, NC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
A’ fastadhÌre 1
- Duke Cancer Institute, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
A’ fastadhÌre 1 tràth
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mìle air falbh
UNC Pleural Fluid Registry
A’ fastadhSgrùdadh amharc
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A’ fastadhÌre 2
- University of North Carolina, Chapel Hill · 10 mìle air falbh
Sgrùdaidhean Ailseachadh nan Sgamhan ann am bailtean eile
- Houston, TX78 sgrùdaidhean
- Boston, MA62 sgrùdaidhean
- New York City, NY60 sgrùdaidhean
- Los Angeles, CA45 sgrùdaidhean
- Washington, DC41 sgrùdaidhean
- Arlington, VA41 sgrùdaidhean
- Chicago, IL41 sgrùdaidhean
- Nashville, TN40 sgrùdaidhean
- Baltimore, MD40 sgrùdaidhean
- St. Louis, MO39 sgrùdaidhean
- Columbus, OH37 sgrùdaidhean
- Philadelphia, PA36 sgrùdaidhean
Sgrùdaidhean eile ann an Durham
- Aillse a' bhroilleach63 sgrùdaidhean
- Aillse (gach seòrsa)58 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag39 sgrùdaidhean
- Myeloma iomaill37 sgrùdaidhean
- Ailse metastatach33 sgrùdaidhean
- Leukemia myeloid geur33 sgrùdaidhean
- Aillse Prostata32 sgrùdaidhean
- Aillse colorectal28 sgrùdaidhean
- Leukemia Lymphocytic Cronach27 sgrùdaidhean
- Cancer Ovarian27 sgrùdaidhean
- Fàilligeadh a' Chridhe26 sgrùdaidhean
- Cancer Pancreatic24 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.